Is the price fair?
What RMD's price assumes
ResMed trades at 22.7× earnings against 42.5× for the median Medical Instruments & Supplies name, cheaper than its own group.
22.7
Trailing P/E · Medical Instruments & Supplies median 42.5 · cheaper than the typical name in its group
- Price / sales
- 5.89
Price / sales · as of 2026-Q1
- Free cash flow yield
- 6.4%
Free cash flow yield · Medical Instruments & Supplies median 3.7%
- Growth the price implies
- +2.4%
Growth the price implies · The price pays for +2.4% free cash flow growth a year for a decade; the business has delivered +61% a year over the last three.
Details›
- Price / book2026-Q1
- 5.02
- EV / EBIT2026-Q1
- 16.6
- EV / sales2026-Q1
- 5.66
- Healthcare median P/E362 names
- 31.5
- Medical Instruments & Supplies median P/E29 names
- 42.5
- Free cash flow, trailing twelve months
- $1.75B
- Market capitalisation
- $27.4B
- 3-year revenue growth
- +11%
- 3-year free cash flow growth
- +61%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $299.00 |
| Its own P/E history, median | $391.34 |
| Its own P/E history, upper quartile | $444.58 |
| 52-week range | $182.82 – $291.49 |
| Today | $235.71 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #3 of 27 by Smart Score